Antigen-specific immune therapy (CNP-106) for treatment of generalised myasthenia gravis: rationale and design of first-in-human randomised controlled trial
Samantha G Brew, Molly Frey, Derrick P McCarthy, Adam Elhofy, Richard J Nowak · 2024
Read Antigen-specific immune therapy (CNP-106) for treatment of generalised myasthenia gravis: rationale and design of first-in-human randomised controlled trial by Samantha G Brew, Molly Frey, Derrick P McCarthy, Adam Elhofy, Richard J Nowak (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11667273.txt.
Description
Samantha Brew and co-authors present a 2024 trial plan for a new immune therapy for myasthenia gravis, a disease where the body attacks its own nerve to muscle links. Current drugs blunt the whole immune system. This nanoparticle therapy aims to retrain it against one target only, the acetylcholine receptor.
The first human trial will enrol about fifty-four patients with the antibody positive general form. It is blinded and placebo controlled across several centres. Safety is the main measure. Disease scores, daily function, and target specific immune marks are also tracked. Animal data suggest the therapy could halt the driver of the disease rather than mask it.
Catalog record
| CREATOR | Samantha G Brew, Molly Frey, Derrick P McCarthy, Adam Elhofy, Richard J Nowak |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 30 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |